BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

GPC Biotech preclinical data

In a mouse Bcr-Abl wild type CML model, RGB-286638 produced a dose-dependent survival benefit that was comparable to Gleevec imatinib and to Sprycel...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >